Differences in Outcomes Between Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer Patients in Upper Middle-Income versus High-Income Countries: A Retrospective Study from 4 Oncology Centers

Dragana Miletić; Marija Kraljević; Emir Sokolović; Majana Soče; Marijana Milović-Kovačević; Simonida Bobić; Timur Cerić; Stjepko Pleština; Semir Bešlija; Inga Marijanović

doi:10.12659/MSM.940356

02 June 2023 : Clinical Research

Differences in Outcomes Between Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer Patients in Upper Middle-Income versus High-Income Countries: A Retrospective Study from 4 Oncology Centers

Dragana Miletić^1ADEF*, Marija Kraljević^1ADEF, Emir Sokolović^2CDE, Majana Soče^3B, Marijana Milović-Kovačević^4B, Simonida Bobić^4B, Timur Cerić^2ABDE, Stjepko Pleština^3A, Semir Bešlija^2AE, Inga Marijanović^15ADE

DOI: 10.12659/MSM.940356

Med Sci Monit 2023; 29:e940356

Authors information Article notes Copyright and License information

Background Material and Methods Results Discussion Conclusions References

Related articles Order reprints Share article Share by email

View HTML version

Figure 3 Overall survival (OS) of patients with metastatic HER2-positive breast cancer in 4 oncology centers in high-income and upper-middle-income countries according to time from diagnosis to start of the treatment, with 2-month cutoff.

Back to the Article

Differences in Outcomes Between Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer Patients in Upper Middle-Income versus High-Income Countries: A Retrospective Study from 4 Oncology Centers

Your Privacy